目的 探究胎盘多肽联合TACE方案治疗晚期原发性肝癌的临床疗效。方法 收集2011年2月—2013年12月辽宁省肿瘤医院收治的原发性肝癌患者88例,随机分为对照组和治疗组,每组44例。对照组采用经导管介入肝动脉灌注化疗栓塞术(TACE)治疗,治疗组在对照组基础上每个TACE疗法周期的1～14 d加用胎盘多肽注射液,8 mL加入250 mL生理盐水中缓慢静脉滴注,1次/d。两组患者均连续治疗4个周期。观察两组的临床疗效,同时比较两组治疗前后Karnofsky评分、免疫功能指标的变化以及药物的毒副反应发生情况。结果 治疗后,对照组和治疗组的总有效率分别为13.64%、31.82%,两组比较差异有统计学意义(P < 0.05)。治疗组患者治疗后Karnofsky评分、CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺高于治疗前,CD⁸⁺低于治疗前,同组比较差异有统计学意义(P < 0.05);治疗组患者治疗后Karnofsky评分、CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺高于对照组,CD⁸⁺低于对照组,两组比较差异具有统计学意义(P < 0.05)。治疗后治疗组患者的白细胞减少、血小板减少、恶心呕吐、腹泻、口腔黏膜减少、贫血等毒副反应的发生率显著低于对照组,两组比较差异具有统计学意义(P < 0.05)。结论 胎盘多肽联合TACE方案治疗晚期原发性肝癌能提高患者的临床疗效,改善生活质量,提高患者的免疫功能和减少化疗药物的毒副反应,值得临床推广应用。

Objective To explore the clinical effects of placenta polypeptide combined with TACE option in treatment of advanced primary liver cancer. Methods The patients with advanced primary liver cancer (88 cases) of Liaoning Cancer Hospital from February 2011 to December 2013 were randomly divided into control and treatment groups, and each group had 44 cases. The patients in the control group were accepted TACE option. The patients in the treatment group were iv administered with Placenta Polypeptide Injection (8 mL diluted with 250 mL physiological saline) on the basis of control group on days 1 — 14 of one cycle, once daily. The patients in two groups were treated for four cycles. After treatment, the efficacy was evaluated, and the changes of Karnofsky score, immune function indexes and drug adverse reaction were compared. Results The efficacies in the control and treatment groups were 13.64% and 31.82%, respectively, and there were differences between two groups (P < 0.05). After treatment, Karnofsky score, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in treatment group were higher than before the treatment, CD⁸⁺ was lower, and the difference was statistically significant in the same group (P < 0.05). Karnofsky score, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in treatment group were higher than those in the control group, while CD⁸⁺ was lower than that in the control group, with the significant difference between two groups (P < 0.05). The incidences of adverse reaction such as leukopenia, thrombocytopenia, nausea, vomiting, diarrhea, reducing of the oral mucosa, and anemia were significantly lower than those in the control group. Conclusion Placenta polypeptide combined with TACE option can improve the clinical curative effect of advanced primary liver cancer, and can improve the quality of life and immune function, while can reduce the adverse reaction of chemotherapy drugs, which is worth clinical popularization and application.